The DOI matches its Crossref record; 74 of the 74 references it cites were found in a registry or an index.
New Tacrine–4-Oxo-4 H-chromene Hybrids as Multifunctional Agents for the Treatment of Alzheimer’s Disease, with Cholinergic, Antioxidant, and β-Amyloid-Reducing Properties
Open accessAbstract
By using fragments endowed with interesting and complementary properties for the treatment of Alzheimer's disease (AD), a new family of tacrine-4-oxo-4H-chromene hybrids has been designed, synthesized, and evaluated biologically. The tacrine fragment was selected for its inhibition of cholinesterases, and the flavonoid scaffold derived from 4-oxo-4H -chromene was chosen for its radical capture and β-secretase 1 (BACE-1) inhibitory activities. At nano- and picomolar concentrations, the new tacrine-4-oxo-4H-chromene hybrids inhibit human acetyl- and butyrylcholinesterase (h-AChE and h-BuChE), being more potent than the parent inhibitor, tacrine. They are also potent inhibitors of human BACE-1, better than the parent flavonoid, apigenin. They show interesting antioxidant properties and could be able to penetrate into the CNS according to the in vitro PAMPA-BBB assay. Among the hybrids investigated, 6-hydroxy-4-oxo- N-{10-[(1,2,3,4-tetrahydroacridin-9-yl)amino]decyl}-4 H-chromene-2-carboxamide (19) shows potent combined inhibition of human BACE-1 and ChEs, as well as good antioxidant and CNS-permeable properties.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A new and rapid colorimetric determination of acetylcholinesterase activity
Ellman, G. L., Courtney, K. D., Andres, V., & Featherstone, R. M. (1961) · Biochemical Pharmacology · doi:10.1016/0006-2952(61)90145-9 · Cited by 27,126
Yung-Chi, C., & Prusoff, W. H. (1973) · Biochemical Pharmacology · doi:10.1016/0006-2952(73)90196-2 · Cited by 12,922
Pietta, P.-G. (2000) · Journal of Natural Products · doi:10.1021/np9904509 · Cited by 4,876
Querfurth, H. W., & LaFerla, F. M. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0909142 · Cited by 4,569
Ou, B., Hampsch-Woodill, M., & Prior, R. L. (2001) · Journal of Agricultural and Food Chemistry · doi:10.1021/jf010586o · Cited by 2,932
Aβ Oligomers – a decade of discovery
Walsh, D. M., & Selkoe, D. J. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04426.x · Cited by 1,938
Extending Applicability of the Oxygen Radical Absorbance Capacity (ORAC−Fluorescein) Assay
Dávalos, A., Gómez-Cordovés, C., & Bartolomé, B. (2004) · Journal of Agricultural and Food Chemistry · doi:10.1021/jf0305231 · Cited by 1,207
High throughput artificial membrane permeability assay for blood–brain barrier
Di, L., Kerns, E. H., Fan, K., McConnell, O. J., & Carter, G. T. (2003) · European Journal of Medicinal Chemistry · doi:10.1016/s0223-5234(03)00012-6 · Cited by 1,195
Multi-target-Directed Ligands To Combat Neurodegenerative Diseases
Cavalli, A., Bolognesi, M. L., Minarini, A., Rosini, M., Tumiatti, V., Recanatini, M., & Melchiorre, C. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm7009364 · Cited by 1,152
The secretases: enzymes with therapeutic potential in Alzheimer disease
De Strooper, B., Vassar, R., & Golde, T. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2009.218 · Cited by 799
Greig, N. H., Utsuki, T., Ingram, D. K., Wang, Y., Pepeu, G., Scali, C., Yu, Q.-S., Mamczarz, J., Holloway, H. W., Giordano, T., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0508575102 · Cited by 734
Lannfelt, L., Blennow, K., Zetterberg, H., Batsman, S., Ames, D., Harrison, J., Masters, C. L., Targum, S., Bush, A. I., Murdoch, R., et al. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70167-4 · Cited by 725
Structure of the Protease Domain of Memapsin 2 (β-Secretase) Complexed with Inhibitor
Hong, L., Koelsch, G., Lin, X., Wu, S., Terzyan, S., Ghosh, A. K., Zhang, X. C., & Tang, J. (2000) · Science · doi:10.1126/science.290.5489.150 · Cited by 711
Control of Peripheral Nerve Myelination by the ß-Secretase BACE1
Willem, M., Garratt, A. N., Novak, B., Citron, M., Kaufmann, S., Rittger, A., DeStrooper, B., Saftig, P., Birchmeier, C., & Haass, C. (2006) · Science · doi:10.1126/science.1132341 · Cited by 703
Targeting acetylcholinesterase and butyrylcholinesterase in dementia
Lane, R. M., Potkin, S. G., & Enz, A. (2005) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145705005833 · Cited by 654
Oxidative stress in the progression of Alzheimer disease in the frontal cortex
Ansari, M. A., & Scheff, S. W. (2010) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e3181cb5af4 · Cited by 605
Cygler, M., Schrag, J. D., Sussman, J. L., Harel, M., Silman, I., Gentry, M. K., & Doctor, B. P. (1993) · Protein Science · doi:10.1002/pro.5560020309 · Cited by 565
CHANGES IN BRAIN CHOLINESTERASES IN SENILE DEMENTIA OF ALZHEIMER TYPE
PERRY, E. K., PERRY, R. H., BLESSED, G., & TOMLINSON, B. E. (1978) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.1978.tb00545.x · Cited by 555
A Structural Motif of Acetylcholinesterase That Promotes Amyloid β-Peptide Fibril Formation
De Ferrari, G. V., Canales, M. A., Shin, I., Weiner, L. M., Silman, I., & Inestrosa, N. C. (2001) · Biochemistry · doi:10.1021/bi0101392 · Cited by 413
PBT2 Rapidly Improves Cognition in Alzheimer's Disease: Additional Phase II Analyses
Faux, N. G., Ritchie, C. W., Gunn, A., Rembach, A., Tsatsanis, A., Bedo, J., Harrison, J., Lannfelt, L., Blennow, K., Zetterberg, H., et al. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-1390 · Cited by 405
Savonenko, A. V., Melnikova, T., Laird, F. M., Stewart, K.-A., Price, D. L., & Wong, P. C. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0710373105 · Cited by 290
Oxidative Stress in Diabetes and Alzheimer's Disease
Reddy, V. P., Zhu, X., Perry, G., & Smith, M. A. (2009) · Journal of Alzheimer's Disease · doi:10.3233/jad-2009-1013 · Cited by 280
Fernández-Bachiller, M. I., Pérez, C., González-Muñoz, G. C., Conde, S., López, M. G., Villarroya, M., García, A. G., & Rodríguez-Franco, M. I. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100329q · Cited by 268
Self-citationAmyloid–cholinesterase interactions: Implications for Alzheimer’s disease
Inestrosa, N. C., Dinamarca, M. C., & Alvarez, A. (2008) · The FEBS Journal · doi:10.1111/j.1742-4658.2007.06238.x · Cited by 261
Rodríguez-Franco, M. I., Fernández-Bachiller, M. I., Pérez, C., Hernández-Ledesma, B., & Bartolomé, B. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm050746d · Cited by 248
Self-citationShimmyo, Y., Kihara, T., Akaike, A., Niidome, T., & Sugimoto, H. (2008) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2008.01.017 · Cited by 234
Rational Approach To Discover Multipotent Anti-Alzheimer Drugs
Rosini, M., Andrisano, V., Bartolini, M., Bolognesi, M. L., Hrelia, P., Minarini, A., Tarozzi, A., & Melchiorre, C. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm049112h · Cited by 226
Tacrine Derivatives and Alzheimers Disease
Tumiatti, V., Minarini, A., Bolognesi, M. L., Milelli, A., Rosini, M., & Melchiorre, C. (2010) · Current Medicinal Chemistry · doi:10.2174/092986710791111206 · Cited by 225
The impact of flavonoids on memory: physiological and molecular considerations
Spencer, J. P. E. (2009) · Chemical Society Reviews · doi:10.1039/b800422f · Cited by 217
Targeting acetylcholinesterase to treat neurodegeneration
Holzgrabe, U., Kapková, P., Alptüzün, V., Scheiber, J., & Kugelmann, E. (2007) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.11.2.161 · Cited by 217
Targeting beta-amyloid pathogenesis through acetylcholinesterase inhibitors
Castro, A., & Martinez, A. (2006) · Current Pharmaceutical Design · doi:10.2174/138161206778792985 · Cited by 207
Acetylcholinesterase promotes beta-amyloid plaques in cerebral cortex
Rees, T. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00230-0 · Cited by 207
A Small Molecule Targeting the Multifactorial Nature of Alzheimer's Disease
Cavalli, A., Bolognesi, M. L., Capsoni, S., Andrisano, V., Bartolini, M., Margotti, E., Cattaneo, A., Recanatini, M., & Melchiorre, C. (2007) · Angewandte Chemie International Edition · doi:10.1002/anie.200700256 · Cited by 179
Camps, P., Formosa, X., Galdeano, C., Muñoz-Torrero, D., Ramírez, L., Gómez, E., Isambert, N., Lavilla, R., Badia, A., Clos, M. V., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900859q · Cited by 173
Self-citationSpencer, J. P. E. (2010) · Proceedings of the Nutrition Society · doi:10.1017/s0029665110000054 · Cited by 163
Fernández‐Bachiller, M. I., Pérez, C., Campillo, N. E., Páez, J. A., González‐Muñoz, G. C., Usán, P., García‐Palomero, E., López, M. G., Villarroya, M., García, A. G., et al. (2009) · ChemMedChem · doi:10.1002/cmdc.200800414 · Cited by 159
Self-citationAlzheimer Disease and the Role of Free Radicals in the Pathogenesis of the Disease
Perry, G. L., Moreira, P. I., Santos, M. S., Oliveira, C. R., Shenk, J. C., Nunomura, A., Smith, M. A., & Zhu, X. (2008) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152708783885156 · Cited by 155
Multipotent antioxidants: from screening to design
Zhang, H., Yang, D., & Tang, G.-Y. (2006) · Drug Discovery Today · doi:10.1016/j.drudis.2006.06.007 · Cited by 137
Marco, J. L., Leon, R. M., Ríos, C. D. L., Samadi, A., Bartolini, M., Andrisano, V., Huertas, Ó., Barril, X., Luque, F. J., Rodríguez-Franco, M. I., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm801292b · Cited by 137
Self-citationShimmyo, Y., Kihara, T., Akaike, A., Niidome, T., & Sugimoto, H. (2007) · Journal of Neuroscience Research · doi:10.1002/jnr.21476 · Cited by 130
Carlier, P. R., Chow, E. S. ‐., Han, Y., Liu, J., Yazal, J. E., & Pang, Y. (1999) · Journal of Medicinal Chemistry · doi:10.1021/jm990224w · Cited by 129
Ermolieff, J., Loy, J. A., Koelsch, G., & Tang, J. (2000) · Biochemistry · doi:10.1021/bi001494f · Cited by 127
Bolognesi, M. L., Cavalli, A., & Melchiorre, C. (2008) · Neurotherapeutics · doi:10.1016/j.nurt.2008.10.042 · Cited by 126
All-transretinoic acid as a novel therapeutic strategy for Alzheimer’s disease
Lee, H. P., Casadesús, G., Zhu, X., Lee, H., Perry, G. L., Smith, M. A., Gustaw‐Rothenberg, K., & Lerner, A. J. (2009) · Expert Review of Neurotherapeutics · doi:10.1586/ern.09.86 · Cited by 124
Fang, L., Appenroth, D., Decker, M. W., Kiehntopf, M., Roegler, C., Deufel, T., Fleck, C., Peng, S., Zhang, Y., & Lehmann, J. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm701491k · Cited by 116
Beking, K., & Vieira, A. V. (2010) · Public Health Nutrition · doi:10.1017/s1368980009992990 · Cited by 116
Pavón, F. J., Bilbao, A., Hernández‐Folgado, L., Cippitelli, A., Jagerovic, N., Abellán, G., Rodríguez-Franco, M. I., Serrano, A., Macías, M., de Heras, R. G., et al. (2006) · Neuropharmacology · doi:10.1016/j.neuropharm.2006.03.029 · Cited by 115
Self-citationArce, M. P., Rodrı́guez-Franco, M. I., González-Muñoz, G. C., Pérez, C., López, B., Villarroya, M., López, M. G., Garcı́a, A. G., & Conde, S. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900628z · Cited by 109
Self-citationOsseni, R., DEBBASCH, C., Christen, M. O., Rat, P., & Warnet, J. (1999) · Toxicology in Vitro · doi:10.1016/s0887-2333(99)00050-8 · Cited by 107
Cerebral blood flow and cognitive responses to rivastigmine treatment in Alzheimer’s disease
Venneri, A., Shanks, M. F., Staff, R. T., Pestell, S. J., Forbes‐McKay, K., Gemmell, H. G., & Murray, A. D. (2002) · Neuroreport · doi:10.1097/00001756-200201210-00020 · Cited by 99
Antioxidant capacity of the neurohormone melatonin
Sofic, E., Rimpapa, Z., Kundurović, Z., Šapčanin, A., Tahirović, I., Rustembegovic, A., & Cao, G. (2005) · Journal of Neural Transmission · doi:10.1007/s00702-004-0270-4 · Cited by 97
Mancini, F., Simone, A. D., & Andrisano, V. (2011) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-011-4963-x · Cited by 97
Gu, F., Zhu, M., Shi, J., Hu, Y., & Zhao, Z. Y. (2008) · Neuroscience Letters · doi:10.1016/j.neulet.2008.05.050 · Cited by 85
Saxena, A., Fedorko, J. M., Vinayaka, C. R., et al. (2003) · European Journal of Biochemistry · doi:10.1046/j.1432-1033.2003.03837.x · Cited by 80
Empirical evidence of neuroprotection by dual cholinesterase inhibition in Alzheimer??s disease
Venneri, A., McGeown, W. J., & Shanks, M. F. (2005) · Neuroreport · doi:10.1097/00001756-200502080-00006 · Cited by 64
Viayna, E., Gómez, T., Galdeano, C., Ramírez, L., Ratia, M., Badía, A., Clos, M. V., Verdaguer, E., Junyent, F., Camins, A., et al. (2010) · ChemMedChem · doi:10.1002/cmdc.201000322 · Cited by 63
Self-citationSpuch, C., Antequera, D., Fernández‐Bachiller, M. I., Rodrı́guez-Franco, M. I., & Carro, E. (2009) · Neurotoxicity Research · doi:10.1007/s12640-009-9121-2 · Cited by 62
Self-citationGrossberg, G. T., Pejović, V., Miller, M. L., & Graham, S. M. (2009) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000200013 · Cited by 59
BACE Inhibitors as Potential Drugs for the Treatment of Alzheimers Disease: Focus on Bioactivity
Evin, G. M., Lessène, G., & Wilkins, S. (2011) · Recent Patents on CNS Drug Discovery · doi:10.2174/157488911795933938 · Cited by 59
Cholinesterase inhibition: is there evidence for disease-modifying effects?
Shanks, M. F., Kivipelto, M., Bullock, R. A., & Lane, R. M. (2009) · Current Medical Research and Opinion · doi:10.1185/03007990903209332 · Cited by 58
Fu, H., Li, W., Luo, J., Lee, N. T. K., Li, M., Tsim, K. W. K., Pang, Y., Youdim, M. B. H., & Han, Y. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.11.068 · Cited by 57
González-Muñoz, G. C., Arce, M. P., López, B., Pérez, C., Romero, A., del Barrio, L., Martin‐de‐Saavedra, M. D., Egea, J., Leon, R. M., Villarroya, M., et al. (2011) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2011.03.003 · Cited by 55
Self-citationMeasuring human β-secretase (BACE1) activity using homogeneous time-resolved fluorescence
Kennedy, M. E., Wang, W., Song, L., Lee, J., Zhang, L., Wong, G., Wang, L., & Parker, E. M. (2003) · Analytical Biochemistry · doi:10.1016/s0003-2697(03)00253-7 · Cited by 54
González-Muñoz, G. C., Arce, M. P., López, B., Pérez, C., Villarroya, M., López, M. G., García, A. G., Conde, S., & Rodríguez-Franco, M. I. (2010) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2010.09.039 · Cited by 52
Self-citationDogterom, P., Nagelkerke, J. F., & Mulder, G. J. (1988) · Biochemical Pharmacology · doi:10.1016/0006-2952(88)90356-5 · Cited by 50
Rodrı́guez-Franco, M. I., Fernández‐Bachiller, M. I., Pérez, C., Castro, A., & Martı́nez, A. (2005) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2005.07.019 · Cited by 50
Self-citationGarcía‐Palomero, E., Muñoz, P., Usán, P., Garcia, P., Delgado, E., de Austria, C., Valenzuela, R., Rubio, L., Medina, M., & Martı́nez, A. (2008) · Neurodegenerative Diseases · doi:10.1159/000113688 · Cited by 45
Marcinkeviciene, J. A., Luo, Y., Graciani, N. R., Combs, A. P., & Copeland, R. A. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m101896200 · Cited by 43
Treatment of Alzheimer’s disease in the long-term-care setting
Smith, D. A. (2009) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp070622 · Cited by 41
Effects of cholinesterase inhibition on brain white matter volume in Alzheimer's disease
Venneri, A., & Lane, R. M. (2009) · Neuroreport · doi:10.1097/wnr.0b013e3283207d21 · Cited by 34
Reviriego, F., Rodrı́guez-Franco, M. I., Navarro, P., García‐España, E., Liu‐González, M., Verdejo, B., & Doménech‐Carbó, A. (2006) · Journal of the American Chemical Society · doi:10.1021/ja064657h · Cited by 32
Self-citationMaroto, M., de Diego, A. M. G., Albiñana, E., Fernández‐Morales, J., Caricati‐Neto, A., Jurkiewicz, A., Yáñez, M., Rodrı́guez-Franco, M. I., Conde, S., Arce, M. P., et al. (2011) · Cell Calcium · doi:10.1016/j.ceca.2011.06.006 · Cited by 20
Self-citationMartin, I., Aspée, A., Torres, P., Lissi, E. A., & López‐Alarcón, C. (2009) · Journal of Medicinal Food · doi:10.1089/jmf.2009.0024 · Cited by 20
β-Amyloid peptide as a target for treatment of Alzheimer’s disease
Conde, S. (2002) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.12.4.503 · Cited by 9
Cited by
Organocatalysis in Inert C–H Bond Functionalization
Qin, Y., Zhu, L., & Luo, S. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00657 · Cited by 785
Acetylcholinesterase inhibitors as Alzheimer therapy: from nerve toxins to neuroprotection
Singh, M., Kaur, M., Kukreja, H., Chugh, R., Silakari, O., & Singh, D. (2013) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2013.09.050 · Cited by 364
Sharma, P., Srivastava, P., Seth, A., Tripathi, P. N., Banerjee, A. G., & Shrivastava, S. K. (2019) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2018.12.006 · Cited by 331
Guzior, N., Wi.eckowska, A., Panek, D., & Malawska, B. (2014) · Current Medicinal Chemistry · doi:10.2174/0929867321666141106122628 · Cited by 323
Agis-Torres, A., Sollhuber, M., Fernandez, M., & Sanchez-Montero, J. M. (2014) · Current Neuropharmacology · doi:10.2174/1570159x113116660047 · Cited by 202
Metadata
- Authors
- Fernández-Bachiller, M. I., Pérez, C., Monjas, L., Rademann, J., & Rodríguez-Franco, M. I.
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2012-01-27
- Volume
- 55
- Issue
- 3
- Pages
- 1303-1317
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W2099853010
- Cited by
- 268
- References
- 74
- FWCI
- 15.69
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.